Stay updated with breaking news from Alkermes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Gainers Abri SPAC I, Inc. (NASDAQ:ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination wit...
Alkermes announced initial results from a study evaluating its investigational orexin-2 receptor agonist in development for narcolepsy.
Alkermes CEO Reflects on Living Company Purpose
Alkermes stock plummeted to its lowest price since last December on disappointing test results for its experimental narcolepsy treatment. The post Alkermes…
UBS Group began coverage on shares of Alkermes (NASDAQ:ALKS – Free Report) in a research report report published on Tuesday, Marketbeat Ratings reports. The firm issued a neutral rating and a $31.00 price target on the stock. A number of other equities research analysts have also weighed in on the company. StockNews.com lowered Alkermes from […]